Madri­gal shares soar on promis­ing PhII NASH da­ta, stok­ing hopes for a new con­tender

You can add Madri­gal Phar­ma­ceu­ti­cals $MDGL to your list of NASH con­tenders — and a soar­ing share price this morn­ing to un­der­score the block­buster mar­ket it’s aim­ing at.

The key end­points re­port­ed this morn­ing cen­ter on the res­o­lu­tion of NASH, with 56% of the pa­tients in the MGL-3196 group see­ing a greater than two point re­duc­tion in their NAS score, com­pared to 32% in the place­bo arm af­ter 36 weeks. And among the 12-week re­spon­ders the score was high­er, at 70%.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER